Patents by Inventor Angelica Linton

Angelica Linton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Patent number: 7151105
    Abstract: The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: December 19, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Angelica Linton, John Howard Tatlock
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Patent number: 7148226
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: November 19, 2003
    Date of Patent: December 12, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen Borchardt, Javier Gonzalez, Hui Li, Maria Angelica Linton, John Howard Tatlock
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase
    Patent number: 7115658
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: October 3, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Peter Scott Dragovich, Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Maria Angelica Linton, John Howard Tatlock, Ru Zhou, Thomas Jay Prins, Melwyn A. Abreo
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Publication number: 20060122399
    Abstract: The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).
    Type: Application
    Filed: August 15, 2005
    Publication date: June 8, 2006
    Inventors: Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Angelica Linton, John Howard Tatlock
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Patent number: 6953858
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 11, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria Angelica Linton, Jeffrey J. Machak, Lennert J. Mitchell, Jr., Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Pharmaceutical compositions and methods for their use
    Publication number: 20040224960
    Abstract: The present invention relates to pharmaceutical compositions and to methods for their use in decreasing cytochrome P450 (CYP450) enzyme activity. The present invention also relates to methods of increasing the bioavailability of a compound in a mammal. Additionally, the present invention relates to methods of decreasing the metabolism of certain compounds in a mammal that are metabolized by the cytochrome P450 enzyme. Furthermore, the present invention relates to pharmaceutical compositions comprising at least one compound metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I).
    Type: Application
    Filed: February 17, 2004
    Publication date: November 11, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Peter Scott Dragovich, Javier Gonzalez, Hui Li, Maria Angelica Linton, John Howard Tatlock
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Publication number: 20040023958
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.
    Type: Application
    Filed: May 9, 2003
    Publication date: February 5, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Peter Scott Dragovich, Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Maria Angelica Linton, John Howard Tatlock, Ru Zhou, Thomas Jay Prins, Melwyn A. Abreo
  • Compounds, pharmaceutical compositions, and methods for stimulating neuronal growth and elongation
    Patent number: 6630472
    Abstract: Compounds that inhibit the peptidyl-prolyl isomerase (rotamase) enzyme activity of the FK-506 binding protein (FKBP) and compositions comprising these compounds are described. The FKBP-inhibiting compounds have a bicyclic [3.3.1], [4.3.1] or polycyclic azaamide nucleus. Pharmaceutical compositions containing such compounds help stimulate the outgrowth of neurites in nerve cells and augmenting nerve regeneration. Methods of treating nerve cells with such compositions are useful to promote repair of neuronal damage caused by disease and physical trauma.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: October 7, 2003
    Assignee: Pfizer Inc
    Inventors: Susumu Katoh, Hiroshi Kawakami, Hiroki Tada, Maria Angelica Linton, Vincent Kalish, John Howard Tatlock, Jesus Ernesto Villafranca